Natriuretic peptides as a target of modern pharmacotherapy;Peptydy natriuretyczne jako cel nowoczesnej farmakoterapii

Farmaceutyczny Przeglad Naukowy

Volumn 7, Issue 1, 2010, Pages 31-37

  Dobrek, Łukasz ^a   Thor, Piotr ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Natriuretic peptides; Neutral endopeptidase inhibitors (NEPI); Vasopeptidase inhibitors (VPI)

Indexed keywords

ENKEPHALINASE INHIBITOR; NATRIURETIC FACTOR; PROTEIN INHIBITOR; VASOPEPTIDASE INHIBITOR;

ARTICLE; ATHEROSCLEROSIS; DRUG ACTIVITY; DRUG TARGETING; ELECTROLYTE BALANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUID BALANCE; HUMAN;

EID: 77953395322     PISSN: 14255073     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. de Bold AJ i wsp. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
2. Dratwa A. Urodylatyna - natriuretyczny peptyd syntetyzowany w nerkach. Med Wet 2007; 63: 41-43.
3. Han B, Hasin Y. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther 2003; 17: 41-52.
4. Yap LB. B-type natriuretic peptide and the right heart. Heart Fail Rev 2004; 9: 99-105.
5. Sharp A, Mayet J. The utility of BNP in clinical practice. J Renin Angiotensin Aldosterone Syst 2004; 5: 53-58.
6. Sagnella GA. Practical implications of current natriuretic peptide research. J Renin Angiotensin Aldosterone Syst 2000; 1: 304-315.
7. Menezes L I wsp. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. J Renin Angiotensin Aldosterone Syst 2004; 5: 121-129.
8. Grabowski M, Orłowska-Baranowska E. Peptyd natriuretyczny typu B w przeroście lewej komory serca. Folia Cardiol 2003; 10: 431-436.
9. Naruko T i wsp. C-type natriuretic peptide in human coronary artherosclerotic lesions. Circulation 1996; 94: 3103-3108.
10. de Lemos JA I wsp. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Eng J Med 2001; 345: 1014-1021.
11. Arakawa N i wsp. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 1994; 85: 334-340.
12. John SW. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267: 679-681.
13. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990; 16: 301-307.
14. Ogawa Y i wsp. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 1994; 93: 1911-1921.
15. Yap LB i wsp. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 2004; 37: 847-856.
16. Yap LB i wsp. Natriuretic peptides, respiratory disease and the right heart. Chest 2004; 126: 1330-1336.
17. Crozier IG i wsp. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet 1986; 2: 1242-1245.
18. Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst 2002; 3: 90-95.
19. Dawson A, Struthers AD. Vasopeptidase inhibitors in heart failure. J Renin Angiotensin Aldosterone Syst 2002; 3: 156-159.
20. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors. Novel therapy for patients with cardiovascular disorders. Drugs 2003; 63: 2185-2202.